PARP inhibitors in ovarian cancer: where are we now?

 

Authors

  • C. Marchetti Department of Gynaecological and Obstetrical Sciences and Urological Sciences, Università di Roma “Sapienza”, Roma, Italy.
  • P. Benedetti Panici Department of Gynaecological and Obstetrical Sciences and Urological Sciences, Università di Roma “Sapienza”, Roma, Italy.
  • S. Kaye The Royal Marsden National Health Service Foundation Trust and The Institute of Cancer Research, Sycamore House, Downs Rd, Sutton, Surrey SM2 5PT, UK.

Keywords:

BRCA1/2, ovarian cancer, polyadenosine diphosphate-ribose polymerase (PARP) inhibitors

Abstract

Ovarian cancer is the most important cause of gynaecological cancer-related mortality. Although the combination of radical surgery and platinum-taxane-based chemotherapy is initially effective, most women will relapse, requiring further treatments. The poor outcome and the lack of effective chemotherapeutic regimens at recurrence have stimulated the exploration of new strategies. Research has been recently focused on targeted therapies and the family of polyadenosine diphosphate-ribose polymerase (PARP) inhibitors seems to be one of the most promising alternatives. The aim of this review is to summarize recent research and clinical progress with PARP inhibitors as novel targeting agents in ovarian cancer.

Downloads

Published

2013-10-15

How to Cite

1.
Marchetti C, Panici PB, Kaye S. PARP inhibitors in ovarian cancer: where are we now?  . CBN [Internet]. 2013 Oct. 15 [cited 2024 Dec. 4];1(1):4-8. Available from: https://journals.aboutscience.eu/index.php/cancerbreakingnews/article/view/247

Issue

Vol. 1 No. 1 (2013): January - December 2013

Section

Review

License

Articles published in Cancer Breaking News are distributed under the CC Attribution-NonCommercial-NoDerivatives 4.0 license, which allows third parties to copy and redistribute the material providing appropriate credit and a link to the license but does not allow to use the material for commercial purposes and to use the material if it has been remixed, transformed or built upon.